Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Dimainvest is a holding company owned by Umberto Di Maio, the controlling shareholder of Shedir Pharma Group.
Shedir Pharma Group manufactures and distributes nutraceuticals, cosmetics and medical devices. The company is headquartered in Piano di Sorrento, Italy.
Oaklins Italy’s parent company, Banca Akros, acted as the appointed broker for the collection of shares in the voluntary public tender offer for 11.9% of Shedir Pharma Group’s shares by Dimainvest.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Aprenda másOmer Engineering has completed an IPO
Omer Engineering Ltd. has successfully launched its IPO on the Tel Aviv Stock Exchange, pricing shares as part of a plan to raise approximately US$94 million at an implied pre-money valuation of around US$313 million. The offering included both newly issued shares and a secondary sale by existing shareholders, who retained a significant majority stake post-IPO. This transaction underscores strong investor interest in scaling the company’s operations and enhancing its capital.
Aprenda másSmart Capital has finalized a rights issue
Smart Capital S.p.A. has finalized a rights issue to continue executing its growth plan and increase its investment capacity. The fundraising supports the expansion of its investment portfolio and the strengthening of its positions in higher-quality investee companies with stronger growth prospects.
Aprenda más